A Case of Bowel Perforation during Temsirolimus Treatment for Metastatic Renal Cell Carcinoma

Treatment outcomes for metastatic Renal Cell Carcinoma (mRCC) have improved with the use of molecular-targeted drugs. However, we should manage several kinds of Adverse Event (AE) more carefully. We report a case of bowel perforation during temsirolimus treatment for metastatic Renal Cell Carcinoma (RCC). A 59-year-old male with left RCC and left supraclavicular lymph node and lung metastases underwent radical nephrectomy in February 2014. Temsirolimus was started after surgery, and Computed Tomography (CT) 3 months later showed shrinkage of the metastases. However, after fourteen courses of temsirolimus treatment, the patient suffered from severe right lower abdominal pain, and CT showed ascites and free air in the anterior surface of the liver. He was diagnosed with bowel perforation, and emergent surgery was performed. After the surgery and antibiotic treatment, the patient recovered. We have to keep in mind the risk of bowel perforation during temsirolimus treatment.